Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 1
1951 3
1960 1
1961 3
1962 3
1963 3
1964 15
1965 9
1966 11
1967 11
1968 11
1969 8
1970 13
1971 11
1972 20
1973 21
1974 13
1975 16
1976 29
1977 18
1978 10
1979 14
1980 17
1981 21
1982 31
1983 27
1984 45
1985 55
1986 50
1987 43
1988 56
1989 74
1990 48
1991 51
1992 42
1993 55
1994 75
1995 62
1996 65
1997 62
1998 76
1999 87
2000 90
2001 90
2002 103
2003 112
2004 105
2005 129
2006 131
2007 111
2008 129
2009 118
2010 114
2011 130
2012 127
2013 136
2014 165
2015 155
2016 157
2017 149
2018 147
2019 163
2020 194
2021 225
2022 238
2023 210
2024 94

Text availability

Article attribute

Article type

Publication date

Search Results

4,439 results

Results by year

Filters applied: . Clear all
Page 1
ZBP1 Protects Against mtDNA-Induced Myocardial Inflammation in Failing Hearts.
Enzan N, Matsushima S, Ikeda S, Okabe K, Ishikita A, Yamamoto T, Sada M, Miyake R, Tsutsui Y, Nishimura R, Toyohara T, Ikeda Y, Shojima Y, Miyamoto HD, Tadokoro T, Ikeda M, Abe K, Ide T, Kinugawa S, Tsutsui H. Enzan N, et al. Among authors: ikeda s. Circ Res. 2023 Apr 28;132(9):1110-1126. doi: 10.1161/CIRCRESAHA.122.322227. Epub 2023 Mar 28. Circ Res. 2023. PMID: 36974722 Free PMC article.
Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trial.
Otsubo K, Kishimoto J, Ando M, Kenmotsu H, Minegishi Y, Horinouchi H, Kato T, Ichihara E, Kondo M, Atagi S, Tamiya M, Ikeda S, Harada T, Takemoto S, Hayashi H, Nakatomi K, Kimura Y, Kondoh Y, Kusumoto M, Ichikado K, Yamamoto N, Nakagawa K, Nakanishi Y, Okamoto I. Otsubo K, et al. Among authors: ikeda s. Eur Respir J. 2022 Dec 15;60(6):2200380. doi: 10.1183/13993003.00380-2022. Print 2022 Dec. Eur Respir J. 2022. PMID: 35361630 Clinical Trial.
Edoxaban for 12 Months Versus 3 Months in Patients With Cancer With Isolated Distal Deep Vein Thrombosis (ONCO DVT Study): An Open-Label, Multicenter, Randomized Clinical Trial.
Yamashita Y, Morimoto T, Muraoka N, Oyakawa T, Umetsu M, Akamatsu D, Nishimoto Y, Sato Y, Takada T, Jujo K, Minami Y, Ogihara Y, Dohi K, Fujita M, Nishikawa T, Ikeda N, Hashimoto G, Otsui K, Mori K, Sueta D, Tsubata Y, Shoji M, Shikama A, Hosoi Y, Tanabe Y, Chatani R, Tsukahara K, Nakanishi N, Kim K, Ikeda S, Mo M, Yoshikawa Y, Kimura T; ONCO DVT Study Investigators. Yamashita Y, et al. Among authors: ikeda s. Circulation. 2023 Nov 21;148(21):1665-1676. doi: 10.1161/CIRCULATIONAHA.123.066360. Epub 2023 Aug 28. Circulation. 2023. PMID: 37638968 Clinical Trial.
Scleral PERK and ATF6 as targets of myopic axial elongation of mouse eyes.
Ikeda SI, Kurihara T, Jiang X, Miwa Y, Lee D, Serizawa N, Jeong H, Mori K, Katada Y, Kunimi H, Ozawa N, Shoda C, Ibuki M, Negishi K, Torii H, Tsubota K. Ikeda SI, et al. Nat Commun. 2022 Oct 10;13(1):5859. doi: 10.1038/s41467-022-33605-1. Nat Commun. 2022. PMID: 36216837 Free PMC article.
Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated EGFR.
Miyauchi E, Morita S, Nakamura A, Hosomi Y, Watanabe K, Ikeda S, Seike M, Fujita Y, Minato K, Ko R, Harada T, Hagiwara K, Kobayashi K, Nukiwa T, Inoue A; North-East Japan Study Group. Miyauchi E, et al. Among authors: ikeda s. J Clin Oncol. 2022 Nov 1;40(31):3587-3592. doi: 10.1200/JCO.21.02911. Epub 2022 Aug 12. J Clin Oncol. 2022. PMID: 35960896 Free PMC article. Clinical Trial.
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA.
John T, Sakai H, Ikeda S, Cheng Y, Kasahara K, Sato Y, Nakahara Y, Takeda M, Kaneda H, Zhang H, Maemondo M, Minato K, Hisada T, Misumi Y, Satouchi M, Hotta K, Li A, Oukessou A, Lu S. John T, et al. Among authors: ikeda s. Int J Clin Oncol. 2022 Apr;27(4):695-706. doi: 10.1007/s10147-022-02120-0. Epub 2022 Feb 19. Int J Clin Oncol. 2022. PMID: 35182247 Free PMC article. Clinical Trial.
Aslanger's sign in 12-lead electrocardiogram.
Takahashi K, Morioka H, Uemura S, Okura T, Sakaue T, Enomoto D, Ikeda S. Takahashi K, et al. Among authors: ikeda s. Oxf Med Case Reports. 2023 Mar 25;2023(3):omad017. doi: 10.1093/omcr/omad017. eCollection 2023 Mar. Oxf Med Case Reports. 2023. PMID: 36993830 Free PMC article. No abstract available.
Biomarker Testing in Patients With Unresectable Advanced or Recurrent Non-Small Cell Lung Cancer.
Sakamoto T, Matsubara T, Takahama T, Yokoyama T, Nakamura A, Tokito T, Okamoto T, Akamatsu H, Oki M, Sato Y, Tobino K, Ikeda S, Mori M, Mimura C, Maeno K, Miura S, Harada T, Nishimura K, Hiraoka M, Kenmotsu H, Fujimoto J, Shimokawa M, Yamamoto N, Nakagawa K. Sakamoto T, et al. Among authors: ikeda s. JAMA Netw Open. 2023 Dec 1;6(12):e2347700. doi: 10.1001/jamanetworkopen.2023.47700. JAMA Netw Open. 2023. PMID: 38100106 Free PMC article.
First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1.
Nishio M, Ohe Y, Ikeda S, Yokoyama T, Hayashi H, Fukuhara T, Sato Y, Tanaka H, Hotta K, Sugawara S, Daga H, Okamoto I, Kasahara K, Naito T, Li L, Gupta RG, Bushong J, Mizutani H. Nishio M, et al. Among authors: ikeda s. Int J Clin Oncol. 2023 Oct;28(10):1354-1368. doi: 10.1007/s10147-023-02390-2. Epub 2023 Aug 7. Int J Clin Oncol. 2023. PMID: 37548831 Free PMC article. Clinical Trial.
4,439 results